ALX Oncology Holdings INC: directors' dealings · United States · SEC (Form 4)

About ALX Oncology Holdings INC

ALX Oncology Holdings Inc. (ticker: ALXO) is a United States-based biotechnology company listed on the NASDAQ, and it operates as a clinical-stage oncology developer rather than a commercial-stage drug maker. Headquartered in South San Francisco, California, the company is focused on immuno-oncology programs designed to help the immune system recognize and attack cancer. ALX Oncology was formed as a Delaware corporation on April 1, 2020, while the company’s operating history dates back to its founding in 2015, according to corporate communications. ([alxoncology.com](https://alxoncology.com/about-us/?utm_source=openai)) The company’s lead asset is evorpacept, a novel CD47-targeted investigational therapy. In practical terms, ALX is pursuing a “don’t eat me” signal blockade strategy: by inhibiting CD47, evorpacept is intended to help the innate immune system identify tumor cells and may enhance the activity of other anti-cancer agents. The pipeline has been built around combination regimens, especially with anti-cancer antibodies, antibody-drug conjugates (ADCs), and selected checkpoint inhibitor approaches. More recently, management has emphasized clinical activity in HER2-positive tumors, gastric and gastroesophageal junction cancers, breast cancer, and certain hematologic malignancies. The company is also advancing ALX2004, an EGFR-targeted ADC that received U.S. FDA IND clearance in 2025 and entered Phase 1 development. ([alxoncology.com](https://alxoncology.com/our-approach/evorpacept/?utm_source=openai)) From a competitive standpoint, ALX Oncology is operating in a highly crowded and scientifically demanding area of cancer drug development. Its investment case depends on whether evorpacept can show a differentiated efficacy-and-safety profile versus other immuno-oncology and targeted therapy combinations, while also translating early clinical signals into registrational opportunities. The most recent updates in 2025 and 2026 highlighted positive data in HER2-positive gastric cancer, indolent B-cell non-Hodgkin lymphoma, and HER2-positive breast cancer, while some prior studies in head and neck cancer did not meet their primary endpoints. That mix of promising signals and clinical setbacks is typical for a development-stage biotech and should be seen as part of the risk/reward framework. ([ir.alxoncology.com](https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-presents-positive-updated-data-aspen-06-phase-2/?utm_source=openai)) Geographically, the company is centered in South San Francisco with a U.S. operating base, while its clinical footprint extends through investigator-sponsored studies, academic collaborations, and multi-center trials. Recent company milestones include additional clinical disclosures at major oncology conferences, continued progress on ALX2004, and a 2026 equity offering that strengthened the balance sheet and funded ongoing development. For investors in France, Belgium, and Switzerland, ALXO should therefore be viewed as a speculative NASDAQ-listed oncology name whose valuation will be driven primarily by clinical readouts, pipeline execution, and future financing needs rather than current product sales. ([ir.alxoncology.com](https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-reports-first-quarter-2026-financial-results-and?utm_source=openai))